TABLE 3.
The results of the analysis of psychopharmacotherapy depending on the carriage of polymorphic variants of CYP2C19*2, CYP2C19*17, and type of CYP2C19 metabolism.
| Variables | Total sample (n = 112) | CYP2C19*2 | p | CYP2C19*17 | p | CYP2C19 metabolism | p | |||
|---|---|---|---|---|---|---|---|---|---|---|
| GG (n = 85) | GA + AA (n = 27) | CC (n = 69) | CT + TT (n = 43) | Normal (n = 78) | Intermediate (n = 26) | |||||
| Sertraline starting dose, mg/day (Me [Q1; Q3]) | 25 [25; 25] | 25 [25; 25] | 25 [25; 37,5] | 0.807 | 25 [25; 25] | 25 [25; 25] | 0.922 | 25 [25; 25] | 25 [25; 25] | 0.826 |
| The dose of sertraline on day 7, mg/day (Me [Q1; Q3]) | 75 [75; 75] | 75 [56,25; 75] | 75 [75; 75] | 0.545 | 75 [75; 75] | 75 [75; 75] | 0.672 | 75 [75; 75] | 75 [75; 75] | 0.934 |
| The dose of sertraline on day 21, mg/day (Me [Q1; Q3]) | 100 [100; 100] | 100 [100; 100] | 100 [87,5; 100] | 0.048 | 100 [100; 100] | 100 [100; 100] | 0.831 | 100 [100; 100] | 100 [100; 100] | 0.245 |
| Antipsychotic, n (%) | 64 (57,1%) | 49 (57,6%) | 15 (55,6%) | 0.848 | 39 (56,5%) | 25 (58,1%) | 0.866 | 47 (60.26%) | 13 (50.00%) | 0.492 |
| Mood stabilizer, n (%) | 15 (13,4%%) | 10 (11,8%) | 5 (18,5%) | 0.369 | 11 (15,9%) | 4 (9,3%) | 0.316 | 10 (12.82%) | 5 (19.23%) | 0.629 |
| Anxiolytic, n (%) | 50 (44,6%) | 39 (45,9%) | 11 (40,7%) | 0.64 | 31 (44,9%) | 19 (44,2%) | 0.939 | 35 (44.87%) | 11 (42.3%) | 0.985 |
| Anticholinergic drug, n (%) | 18 (16,1%) | 13 (15,3%) | 5 (18,5%) | 0.691 | 12 (17,4%) | 6 (14,0%) | 0.63 | 12 (15.38%) | 3 (11,53%) | 0.872 |